🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Scholar Rock Holding Corporation

Scholar Rock Holding Corporation logo
Market Cap: High
Employees: Low

Apitegromab

Scholar Rock Holding Corporation is a biopharmaceutical company focused on developing medicines for serious diseases where protein growth factor signaling plays a critical role. The company advances Apitegromab, targeting spinal muscular atrophy, and SRK-181 for cancer treatments, alongside a pipeline addressing neuromuscular disorders, cancer, and fibrosis.

Tags: biopharmaceutical, cancer, fibrosis, medicine development, neuromuscular disorders, protein growth factors, spinal muscular atrophy

Website

About | About | About | News | Events | ESG | About | About | About | Careers | About | About | Leadership | Directors | About | Contact | Contact | Careers

Symbol: SRRK

Recent Price: $42.91

Industry: Biotechnology

CEO: Dr. Jay Thomas Backstrom M.D., M.P.H.

Sector: Healthcare

Employees: 150

Address: 301 Binney Street, Cambridge, MA 02142

Phone: 857 259 3860

Leadership

  • David Hallal, Chairman of the Scholar Rock Board and Chief Executive Officer of ElevateBio
  • Srini Akkaraju, MD, PhD, Founder & Managing Partner, Samsara BioCapital
  • Jay Backstrom, M.D., MPH, President & CEO
  • Richard Brudnick, Chief Business Officer, Prime Medicine
  • Kristina Burow, Managing Director, ARCH Venture Partners
  • Jeffrey Flier, MD, Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor; Former Dean of Harvard Medical School
  • Michael Gilman, PhD, CEO, Arrakis Therapeutics
  • Katie Peng, Chief Commercial Officer, Denali Therapeutics
  • Joshua Reed, Chief Financial Officer of Omega Therapeutics
  • Akshay Vaishnaw, MD, PhD, Chief Innovation Officer, Alnylam Pharmaceuticals

Last updated: 2024-12-31